Mirvetuximab soravtansine targets FRα on the cell surface, is internalized, and releases DM4, which binds β‑tubulin to disrupt microtubules and induce mitotic arrest/apoptosis. β‑tubulin itself is not the targeted antigen; expression alone does not lead to selective killing.